DTx Europe 2023

Edouard is the Co-Founder and CEO of Tilak Healthcare, a unique video game studio creating clinically validated medical mobile games to help monitor and rehabilitate patients affected by chronic diseases.

For more than 10 years, Edouard worked in the video game industry at Gameloft, a company developing and editing mobile video games, where he successively held the positions of Project manager in Paris, then Lead Producer in New Orleans and finally managing Director of Gameloft Madrid.

Driven by his passion for innovation and technology, he was also a writer for TechCrunch France, covering mobile apps, 2.0 web and entertainment topics.

Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA over 20 years ago. In his current role as Chief Medical Solutions Officer, Matthias is responsible for leveraging GAIA’s decades of DTx medical research and expertise internationally and providing integrated solutions to payer and physician organizations.

After a medical apprenticeship and studies in medical technology, I worked as a scientific
employee at the Federal Institute for Drugs and Medical Devices for more than seven years.
Among others, in the areas of approval of clinical trials with medical devices and vigilance.
The last two years were spent in the field of digital health applications (DiGA) as deputy
head of the according unit. In this area, I was intensively involved in the development of the
German DiGA fast-track and helped to design it. Since January 22, I have been in charge of
market access at Sympatient and now dedicate myself to solving the worldwide anxiety
crisis.

Dr Rayna Patel is a medical doctor & neuroscientist with an MPhil in Translational Medicine. She has extensive experience in academia (Cambridge, Harvard, MIT, Columbia) and was an Associate Fellow of Clare Hall College, Cambridge. Rayna has subsequently held strategic & commercial roles in government policy, tech startups & the Cabinet Office’s Nudge Unit, where she used behavioural science to rewire patient behaviours through digital products.
She is currently CEO and Co-Founder of Vinehealth, a digital platform using a combination of behavioural science and AI to improve the quality of life and survival of cancer patients, whilst generating crucial real-world data to better inform healthcare delivery and drug development.

As co-founder and managing director Christian is in charge of sales, market access, and reimbursement for Sympatient – the first digital anxiety clinic. He has a strong passion for solving complex problems in healthcare systems to ultimately enable better access to care for patients. Christian holds a degree in economics from Jacobs University, an MPhil from the University of Cambridge, and has been a visiting student at Harvard University.

Yury Rozenman is the SVP of Pharmaceutical and Life Sciences at Propeller. In this role, he leads the company’s strategy, vision and oversees execution of all global business development activities. Prior to joining Propeller, Yury was the head of healthcare and life sciences industry partnerships at AWS where he was responsible for the development of life sciences vertical solutions, marketing programs, joint GTM strategy and execution on the global basis. Yury has 30 years of experience within the industry in pharmaceutical research and development both as a team leader and group research manager. He has worked in diagnostics and medical devices, and has been involved in the development and launch of world-class drugs and diagnostic tests.

Arvind joined atai Life Sciences in 2021 as Vice President, Digital Strategy and Operations, and is responsible for establishing and implementing atai’s Digital Therapeutics and Precision Psychiatry strategy. Prior to joining atai, Arvind was the Chief Operating Officer of Oxford VR, where he was responsible for Operations, Strategy, and Business Development. Oxford VR received Breakthrough Device designation from the FDA for the treatment of serious mental illnesses and was acquired by US operator BehaVR in 2022.

Before joining Oxford VR, Arvind was an Investment Manager at Epiris Private Equity (“Epiris”), where he was responsible for the buy-out, management, and digital transformation of companies between £100m – £500m in valuation. At Epiris, Arvind deployed and exited over £400m and £200m of capital respectively and sat on 9 Executive Boards. Arvind started his professional career at NM Rothschild & Sons where he was Vice President, Healthcare Mergers & Acquisitions.

Arvind holds a Bachelor’s and Master’s degree in Molecular and Cellular Biochemistry from the University of Oxford with dissertations in Cell Cycle Replication (Professor Kearsey) and Vaccinology (Dame Professor Gilbert).